trending Market Intelligence /marketintelligence/en/news-insights/trending/tqpAuyBq0MY2Yj0qm-EqPg2 content esgSubNav
In This List

US FDA to expedite Mesoblast's heart failure treatment in patients with implants

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


US FDA to expedite Mesoblast's heart failure treatment in patients with implants

Mesoblast Ltd's approval application for its mesenchymal precursor cell, or MPC, therapy has been expedited as the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to the product.

The MPC therapy aims to treat heart failure patients with left ventricular systolic dysfunction and left ventricular assist devices.

The designation also allows for priority review of the therapy.

The U.S. FDA granted the designation based on the preliminary results of a placebo-controlled trial. The study reported improved heart function and improved survival rates in patients with heart implants along with a delay in internal bleeding caused by the same.

Mesoblast is conducting a phase 2b trial for the product. The company expects to have results from the trials by the first quarter of 2018.